Der Internist

, 52:518

Diabetische Retinopathie und Makulopathie

Schwerpunkt
  • 271 Downloads

Zusammenfassung

Die diabetische Retinopathie ist die häufigste mikrovaskuläre Komplikation des Diabetes mellitus. Eine frühe Entstehung im Krankheitsverlauf deutet auf ein hohes kardiovaskuläres Allgemeinrisiko. Die frühen Stadien verlaufen symptomlos, daher sind jährliche Screeninguntersuchungen erforderlich. Für jedes Stadium der Retinopathie existieren evidenzbasierte Handlungsempfehlungen, wobei sich allgemeine diabetologische Prinzipien und spezielle ophthalmologische Behandlungen ergänzen. Mit der intravitrealen Injektion von Inhibitoren des Vascular endothelial growth factor (VEGF) wird die bislang nur mäßig erfolgreiche Behandlung der diabetischen Makulopathie möglicherweise in der Zukunft verbessert werden können.

Schlüsselwörter

Diabetes mellitus Retinopathie Mikroangiopathie Makulopathie Vorsorgeuntersuchung 

Diabetic retinopathy and maculopathy

Abstract

Diabetic retinopathy is the most frequent microvascular complication in diabetes. Its early development indicates an increased cardiovascular risk. Since the early stages lack symptoms, yearly screening intervals are mandatory. Each retinopathy level determines evidence-based treatment with mutual interactive contributions from diabetology and ophthalmology. Intravitreal injection of inhibitors of the vascular endothelial growth factor may improve the so far only modestly successful therapy of diabetic macular edema.

Keyword

Diabetes mellitus Retinopathy Microangiopathy Maculopathy Screening 

Literatur

  1. 1.
    Aiello LP, Cahill MT, Wong JS (2001) Systemic considerations in the management of diabetic retinopathy. Am J Ophthalmol 132:760–776PubMedCrossRefGoogle Scholar
  2. 2.
    Al-Kateb H, Mirea L, Xie X et al (2007) Multiple variants in vascular endothelial growth factor (VEGFA) are risk factors for time to severe retinopathy in type 1 diabetes: the DCCT/EDIC genetics study. Diabetes 56:2161–2168PubMedCrossRefGoogle Scholar
  3. 3.
    Bertram B (1997) Prevalence of patients with diabetes mellitus without and with retinopathy in an ophthalmology practice. Ophthalmologe 94:401–404PubMedCrossRefGoogle Scholar
  4. 4.
    Blum M, Kloos C, Muller N et al (2007) Prevalence of diabetic retinopathy. Check-up program of a public health insurance company in Germany 2002–2004. Ophthalmologe 104:499–500, 502–504PubMedCrossRefGoogle Scholar
  5. 5.
    Bringmann A, Iandiev I, Pannicke T et al (2009) Cellular signaling and factors involved in Muller cell gliosis: Neuroprotective and detrimental effects. Prog Retin Eye Res 28:423–451PubMedCrossRefGoogle Scholar
  6. 6.
    Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820PubMedCrossRefGoogle Scholar
  7. 7.
    Chaturvedi N, Porta M, Klein R et al (2008) Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 372:1394–1402PubMedCrossRefGoogle Scholar
  8. 8.
    Chaturvedi N, Sjoelie AK, Porta M et al (2001) Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. Diabetes care 24:284–289PubMedCrossRefGoogle Scholar
  9. 9.
    Chaturvedi N, Sjolie AK, Stephenson JM et al (1998) Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 351:28–31PubMedCrossRefGoogle Scholar
  10. 10.
    Cheung N, Wong TY (2008) Diabetic retinopathy and systemic vascular complications. Prog Retin Eye Res 27:161–176PubMedCrossRefGoogle Scholar
  11. 11.
    Ciulla TA, Rosenfeld PJ (2009) Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration. Curr Opin Ophthalmol 20:166–174PubMedCrossRefGoogle Scholar
  12. 12.
    Deutsche Ophthalmologische Gesellschaft, Retinologische Gesellschaft, Berufsverband der Augenärzte Deutschlands (2010) Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands zur Therapie der diabetischen Makulopathie. www.dog.org/wp-content/uploads/2009/08/Stellungnahme-zur-Therapie-der-diabetischen-Makulopathie-20110208.pdfGoogle Scholar
  13. 13.
    Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRefGoogle Scholar
  14. 14.
    Diabetes Control and Complications Trial Research Group (1996) The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 45:1289–1298CrossRefGoogle Scholar
  15. 15.
    Diabetes Control and Complications Trial Research Group (1998) Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 116:874–886Google Scholar
  16. 16.
    Diabetes Control and Complications Trial Research Group (2000) Effect of pregnancy on microvascular complications in the diabetes control and complications trial. the diabetes control and complications trial research group. Diabetes Care 23:1084–1091CrossRefGoogle Scholar
  17. 17.
    Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW et al (2010) Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117:1064–1077CrossRefGoogle Scholar
  18. 18.
    Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139PubMedCrossRefGoogle Scholar
  19. 19.
    Engelgau MM, Thompson TJ, Herman WH et al (1997) Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes. Diagnostic criteria and performance revisited. Diabetes Care 20:785–791PubMedCrossRefGoogle Scholar
  20. 20.
    Engerman RL, Kern TS (1987) Progression of incipient diabetic retinopathy during good glycemic control. Diabetes 36:808–812PubMedCrossRefGoogle Scholar
  21. 21.
    Frank RN (2004) Diabetic retinopathy. N Engl J Med 350:48–58PubMedCrossRefGoogle Scholar
  22. 22.
    Gaede P, Lund-Andersen H, Parving HH, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580–591PubMedCrossRefGoogle Scholar
  23. 23.
    Gaede P, Vedel P, Larsen N et al (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383–393PubMedCrossRefGoogle Scholar
  24. 24.
    Gerstein HC, Miller ME, Byington RP et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559PubMedCrossRefGoogle Scholar
  25. 25.
    Haritoglou C, Gerss J, Sauerland C et al (2009) Effect of calcium dobesilate on occurrence of diabetic macular oedema (CALDIRET study): randomised, double-blind, placebo-controlled, multicentre trial. Lancet 373:1364–1371PubMedCrossRefGoogle Scholar
  26. 26.
    Hecke MV van, Dekker JM, Stehouwer CD et al (2005) Diabetic retinopathy is associated with mortality and cardiovascular disease incidence: the EURODIAB prospective complications study. Diabetes Care 28:1383–1389PubMedCrossRefGoogle Scholar
  27. 27.
    Hesse L, Grusser M, Hoffstadt K et al (2001) Population-based study of diabetic retinopathy in Wolfsburg. Ophthalmologe 98:1065–1068PubMedCrossRefGoogle Scholar
  28. 28.
    Jonas JB, Schlichtenbrede F (2008) Visual acuity and intraocular pressure after high-dose intravitreal triamcinolone acetonide in selected ocular diseases. Eye 22:869–873PubMedCrossRefGoogle Scholar
  29. 29.
    Keech AC, Mitchell P, Summanen PA et al (2007) Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370:1687–1697PubMedCrossRefGoogle Scholar
  30. 30.
    Keen H, Lee ET, Russell D et al (2001) The appearance of retinopathy and progression to proliferative retinopathy: the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia (Suppl 44) 2:S22–S30Google Scholar
  31. 31.
    Klein R, Klein BE, Moss SE et al (1989) Is blood pressure a predictor of the incidence or progression of diabetic retinopathy? Arch Intern Med 149:2427–2432PubMedCrossRefGoogle Scholar
  32. 32.
    Klein R, Klein BE, Moss SE, Cruickshanks KJ (1998) The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 105:1801–1815PubMedCrossRefGoogle Scholar
  33. 33.
    Klein R, Klein BE, Moss SE, Cruickshanks KJ (1999) Association of ocular disease and mortality in a diabetic population. Arch Ophthalmol 117:1487–1495PubMedGoogle Scholar
  34. 34.
    Klein R, Knudtson MD, Lee KE et al (2008) The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 115:1859–1868PubMedCrossRefGoogle Scholar
  35. 35.
    Klein R, Moss SE, Klein BE et al (1989) The Wisconsin epidemiologic study of diabetic retinopathy. XI. The incidence of macular edema. Ophthalmology 96:1501–1510PubMedGoogle Scholar
  36. 36.
    Krumpaszky HG, Klauss V (1992) Cause of blindness in Bavaria. Evaluation of a representative sample from blindness compensation records of upper Bavaria. Klin Monatsbl Augenheilkd 200:142–146PubMedCrossRefGoogle Scholar
  37. 37.
    Malone JI, Morrison AD, Pavan PR, Cuthbertson DD (2001) Prevalence and significance of retinopathy in subjects with type 1 diabetes of less than 5 years‘ duration screened for the diabetes control and complications trial. Diabetes Care 24:522–526PubMedCrossRefGoogle Scholar
  38. 38.
    Massin P, Bandello F, Garweg JG et al (2010) Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diab Care 33: 2399–2405CrossRefGoogle Scholar
  39. 39.
    McCance DR, Hanson RL, Charles MA et al (1994) Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. BMJ 308:1323–1328PubMedGoogle Scholar
  40. 40.
    Moss SE, Klein R, Klein BE (1996) Cigarette smoking and ten-year progression of diabetic retinopathy. Ophthalmology 103:1438–1442PubMedGoogle Scholar
  41. 41.
    Mühlhauser I, Bender R, Bott U et al (1996) Cigarette smoking and progression of retinopathy and nephropathy in type 1 diabetes. Diabet Med 13:536–543PubMedCrossRefGoogle Scholar
  42. 42.
    Nathan DM, Zinman B, Cleary PA et al (2009) Modern-day clinical course of type 1 diabetes mellitus after 30 years‘ duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983–2005). Arch Intern Med 169:1307–1316PubMedCrossRefGoogle Scholar
  43. 43.
    Nguyen TT, Wang JJ, Wong TY (2007) Retinal vascular changes in pre-diabetes and prehypertension: new findings and their research and clinical implications. Diabetes Care 30:2708–2715PubMedCrossRefGoogle Scholar
  44. 44.
    Patel A, MacMahon S, Chalmers J et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572PubMedCrossRefGoogle Scholar
  45. 45.
    Polak K, Schmetterer L, Riva CE (2002) Influence of flicker frequency on flicker-induced changes of retinal vessel diameter. Invest Ophthalmol Vis Sci 43:2721–2726PubMedGoogle Scholar
  46. 46.
    Porta M, Bandello F (2002) Diabetic retinopathy. A clinical update. Diabetologia 45:1617–1634PubMedCrossRefGoogle Scholar
  47. 47.
    Sang DN, D’Amore PA (2008) Is blockade of vascular endothelial growth factor beneficial for all types of diabetic retinopathy? Diabetologia 51:1570–1573PubMedCrossRefGoogle Scholar
  48. 48.
    Sjolie AK, Klein R, Porta M et al (2008) Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 372:1385–1393PubMedCrossRefGoogle Scholar
  49. 49.
    Spranger J, Hammes HP, Preissner KT et al (2000) Release of the angiogenesis inhibitor angiostatin in patients with proliferative diabetic retinopathy: association with retinal photocoagulation. Diabetologia 43:1404–1407PubMedCrossRefGoogle Scholar
  50. 50.
    Spranger J, Osterhoff M, Reimann M et al (2001) Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes 50:2641–2645PubMedCrossRefGoogle Scholar
  51. 51.
    Stratton IM, Kohner EM, Aldington SJ et al (2001) UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia 44:156–163PubMedCrossRefGoogle Scholar
  52. 52.
    Tong Z, Yang Z, Patel S et al (2008) Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc Natl Acad Sci U S A 105:6998–7003PubMedCrossRefGoogle Scholar
  53. 53.
    Trautner C, Icks A, Haastert B et al (1997) Incidence of blindness in relation to diabetes. A population-based study. Diabetes Care 20:1147–1153PubMedCrossRefGoogle Scholar
  54. 54.
    Uhlmann K, Kovacs P, Boettcher Y et al (2006) Genetics of diabetic retinopathy. Exp Clin Endocrinol Diabetes 114:275–294PubMedCrossRefGoogle Scholar
  55. 55.
    UK Prospective Diabetes Study Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853CrossRefGoogle Scholar
  56. 56.
    UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703–713Google Scholar
  57. 57.
    Virgili G, Menchini F, Dimastrogiovanni AF et al (2007) Optical coherence tomography versus stereoscopic fundus photography or biomicroscopy for diagnosing diabetic macular edema: a systematic review. Invest Ophthalmol Vis Sci 48:4963–4673PubMedCrossRefGoogle Scholar
  58. 58.
    Wong TY, Liew G, Tapp RJ et al (2008) Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies. Lancet 371:736–743PubMedCrossRefGoogle Scholar
  59. 59.
    Wong TY, McIntosh R (2005) Systemic associations of retinal microvascular signs: a review of recent population-based studies. Ophthalmic Physiol Opt 25:195–204PubMedCrossRefGoogle Scholar
  60. 60.
    Wong TY, Mitchell P (2007) The eye in hypertension. Lancet 369:425–435PubMedCrossRefGoogle Scholar
  61. 61.
    Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287:2563–2569CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.5. Medizinische Klinik, Universitätsmedizin MannheimUniversität HeidelbergMannheimDeutschland

Personalised recommendations